[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stargardts-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stargardts-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100256498","rod-and-cone-mediated-function-in-retinal-disease-100256498",false,"NCT02617966","Rod and Cone Mediated Function in Retinal Disease","* INCLUSION CRITERIA:\n* Participant must be five years of age or older.\n* Participant (or legal guardian) must understand and sign the protocol s informed consent document.\n* Participant must be able to cooperate with the testing required for this study.\n\nFor Participants with retinal disease only:\n\n* Participant must have retinal disease, defined as evidence of loss of retinal dysfunction and\u002For degeneration as established by standard clinical methods including perimetry, ERG and imaging.\n* Participant must have a measurable visual acuity.\n\nFor Healthy Volunteers only:\n\n-Participant must have visual acuity of 20\u002F20 or better, with or without correction (e.g., glasses or contact lens) in at least one eye.\n\nEXCLUSION CRITERIA:\n\n-Participant with changes in pre-retinal media sufficient to obscure a view of the retina.",true,"ALL","5 Years","100 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Background:\n\nRetinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.\n\nObjectives:\n\nTo find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track its changes.\n\nEligibility:\n\nPeople ages 5 and older with:\n\nRetinal disease OR\n\n20\u002F20 vision or better with or without correction in at least one eye\n\nDesign:\n\nParticipants will be screened with medical and eye history and eye exam. Those with retinal disease will also have:\n\nEye imaging: Drops dilate the eye and pictures are taken of it.\n\nVisual field testing: Participants look into a bowl and press a button when they see light.\n\nElectroretinogram (ERG): An electrode is taped to the forehead. Participants sit in the\n\ndark with their eyes patched for 30 minutes. Then they get numbing drops and contact\n\nlenses. Participants watch lights while retina signals are recorded.\n\nVisit 1 will be 3-8 hours. Participants will have up to 6 more visits over 6-12 months. Visits include:\n\nEye exam and imaging\n\nTime course of dark adaptation: Participants view a background light for 5 minutes then\n\npush a button when they see colored light.\n\nDark adapted sensitivity: Participants sit in the dark for 45 minutes. They push a button when\n\nthey see colored light.\n\nFor participants with retinal disease, ERG and visual field testing",[25,26,27],"Retinal Degeneration","Retinitis Pigmentosa","Stargardt's Disease",[29,25,26,27,30],"Retina","Dark Adaptation","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-05-29","ACTUAL",{"date":37,"type":35},"2016-03-24",{"date":39,"type":21},"2029-12-30",{"name":41,"class":42},"National Eye Institute (NEI)","NIH",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100549513","an-observational-study-in-subjects-to-follow-the-progression-of-stargardt-disease-type-1-stgd1-caused-by-bi-allelic-autosomal-recessive-mutations-in-the-abca4-gene-100549513","NCT06435000","An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene","An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene","POLARIS","Inclusion Criteria:\n\n1. Provide written consent\n2. Are male or female aged 12-65 years old\n3. Have a diagnosis of STGD1 caused by bi-allelic likely pathogenic or pathogenic variants in the ABCA4 gene confirmed genotypically by an accredited genotyping laboratory\n4. Have a history of STGD1 progression within the last 2 years, in the opinion of the investigator.\n5. Eligible eye(s) must have:\n\n   1. BCVA of between 24-88 ETDRS letters, inclusive (20\u002F20 - 20\u002F320 Snellen equivalent, 0.0-1.2 logMAR) at the Screening Visit.\n   2. Clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease.\n   3. Fundus autofluorescence (FAF) measurement of definitely decreased autofluorescence (DDAF) as measured by the Central Reading Center (CRC).\n   4. Total lesion must be imaged in its entirety.\n   5. All total lesion borders must be ≥300 microns from all image edges.\n6. Eligible eye(s) must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging.\n\nExclusion Criteria:\n\n1. Are an immediate family member (e.g., child, sibling) of the Sponsor or study site personnel.\n2. Have any concurrent ocular disease that would affect study procedures or outcomes (e.g., cataracts; subjects can be enrolled 90 days after successful cataract surgery) in eligible eyes.\n3. Have two likely pathogenic or pathogenic variants (not STGD1) in autosomal recessive inherited retinal dystrophy (IRD) genes or a single likely pathogenic or pathogenic variant in autosomal dominant or X-linked IRD genes.\n4. Have had any intraocular surgery or thermal laser within 90 days of study entry or any prior thermal laser in the macular region within the eligible eye(s).\n5. Have any major surgical procedure within 30 days of the Screening Visit or planned or anticipated major surgery during the study period.\n6. Are unwilling to stop taking the following products at Screening and throughout the study:\n\n   1. Supplements containing vitamin A or beta-carotene, liver-based products.\n   2. Prescription oral retinoids.\n7. Have actively participated in an investigational therapy study or have received any investigational therapy within 90 days of the Screening Visit or 5 half-lives, whichever is longer. Note: any ophthalmic history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or intravitreal or sub-retinal injections exclude the subject from study participation.\n8. Have known serious allergies to the fluorescein dye that might be used to measure intraocular pressure (IOP), ocular dilating drops, topical ocular anesthetic, or any history of anaphylaxis reaction.\n9. Have a history of amblyopia in the eligible eye(s).\n10. Have any significant ocular or non-ocular disease\u002Fdisorder (or medication and\u002For laboratory test abnormalities) which, in the opinion of the investigator and with concurrence of the Medical Monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or affect the subject's ability to participate in the study.","12 Years","65 Years",{"count":55,"type":21},75,"This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene\n\nThis is a multicenter study which will enroll approximately 75 subjects",[58,27,59,60],"Stargardt","Stargardt Disease","STGD1",[50,62,60,63],"Splicebio","ABCA4","2025-09-18",{"date":66,"type":35},"2025-09-19",{"date":68,"type":35},"2024-03-29",{"date":70,"type":21},"2027-02",{"name":72,"class":73},"Splice Bio","INDUSTRY",20]